FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * EMSTER KURT VON	2. Issuer Name ar CymaBay Ther			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last) (First) (Middle) C/O CYMABAY THERAPEUTICS, INC., 7999 GATEWAY BLVD, SUITE 130	3. Date of Earliest 7 06/05/2018	th/Day/Y	ear)		re title below)		ner (specify b	elow)			
(Street) NEWARK, CA 94560	4. If Amendment, I 06/07/2018	d(Month/Da	ny/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person							
(City) (State) (Zip)		Table I -	Non-l	Derivativ	e Securi	ties Acq	uired, Disposed	of, or Benefic	ially Own	ed	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, if any (Month/Day/Year)	(Instr. 8)	ction	4. Secur (A) or D (Instr. 3,	isposed	of (D)	5. Amount of Securities B Owned Following Reported Transaction(s) (Instr. 3 and 4)		F I	Ownership Form: Direct (D) r Indirect	Beneficial Ownership
		Code	v	Amount	(A) or (D)	Price				I) Instr. 4)	
Common Stock 06/05/2018		Х		2,000	A	\$ 5.75	19,236		I		By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005
Common Stock 06/05/2018		S ⁽¹⁾		920	D	\$ 12.51	18,316		I		By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005
Common Stock							90,000		I)	10, 2003
Common Stock							273,417		I		See footnotes (2) (3)
Reminder: Report on a separate line for each class of securities	beneficially owned o	lirectly or i	Pers in th	sons wh	are not	require	he collection ced to respond trol number.				C 1474 (9-02)
Table I	I - Derivative Securi	ties Acqui	_								
1. Title of Derivative Security (Instr. 3) 2.	(e.g., puts, calls, v 4. 5. Nun Transaction of Code Deriva	mber 6. D Exp ative (Mo	ptions Date Expiration	s, convert ercisable	ible secu	7. Titl of Und Securi	le and Amount derlying ities	(Instr. 5) Bei Ow Fol Rej Tra		Owners Form of Derivat Security Direct (or Indir	Beneficial Ownership (Instr. 4)

		Code	V	(A)	(D)		Expiration Date	Title	Amount or Number of Shares				
Warrant (right to buy)	06/05/2018	X			2,000	09/30/2013	09/30/2018	Common Stock	2,000	\$ 0	0	I	By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
EMSTER KURT VON C/O CYMABAY THERAPEUTICS, INC. 7999 GATEWAY BLVD, SUITE 130 NEWARK, CA 94560	X							

Signatures

/s/ John Heard, as attorney-in-fact	06/11/2018
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This amended Form 4 is being amended to correct the incorrect code used for acquisition of the warrant securities. On June 5, 2018, Kurt von Emster (the "Reporting Person") on behalf of the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005, exercised a warrant to purchase 2,000 shares of CymaBay Therapeutics, Inc. ("CBAY") common stock for \$5.75 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in CBAY's withholding of 920 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 1,080 shares. CBAY also paid \$9.47 to the Reporting Person in lieu of a fractional share.
- Shares are held by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE" together with ABV VI, the "Abingworth Funds"). Abingworth (2) LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth.
- From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the (3) supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.